Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

Vertex. Additionally, the prescribing information for Trikafta has been updated with a boxed warning regarding drug-induced liver injury and liver failure. The boxed warning states liver function ...

Consistent Rise in VRTX’s CF Product Sales Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. In the first nine mont ...

Trikafta was first approved in 2019. It has been used to treat tens of thousands of people with cystic fibrosis, said Vertex's chief medical officer, Carmen Bozic. Write to Katherine Hamilton at ...

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options ... Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently ...

These approvals further cement Vertex’s dominance in the CF market, which remains a significant revenue driver for the company. Trikafta generated $9.9bn in sales in 2023 and is projected to ...

ALYFTREK was non-inferior on ppFEV1 and further decreased sweat chloride compared to TRIKAFTA® - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug ...

Vertex Pharmaceuticals (VRTX ... and lower sweat chloride levels than Trikafta, is another step in achieving this goal.” ...